NCT07028528

Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy

A Randomized Placebo Controlled Trial Assessing the Efficacy of Levagen+ for Treating Symptoms of Diabetic Peripheral Neuropathy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN. Participants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.

Conditions

• Diabetic Peripheral Neuropathy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Levagen+	Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA
OTHER	Placebo	Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2025-06-19
• Last updated: 2025-07-23

Locations

1 site across 1 country: Australia